261710-81-0Relevant articles and documents
HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS
-
Paragraph 000264, (2015/10/05)
ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
HIV protease inhibitors
-
, (2008/06/13)
The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: The effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters
Hagen,Domagala,Gajda,Lovdahl,Tait,Wise,Holler,Hupe,Nouhan,Urumov,Zeikus,Zeikus,Lunney,Pavlovsky,Gracheck,Saunders,VanderRoest,Brodfuehrer
, p. 2319 - 2332 (2007/10/03)
Due largely to the emergence of multi-drug-resistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the pharmaceutical industry. Toward this end, we previously identified a 4-hydroxy-5,6-dihydropyrone lead compound